Brian Druker | Academic Influence

Brian Druker's AcademicInfluence.com Rankings

Brian Druker

Philosophy

#3053

World Rank

#5024

Historical Rank

#1009

USA Rank

Logic

#953

World Rank

#1551

Historical Rank

#323

USA Rank

philosophy Degrees

Download Badge

Philosophy

Brian Druker's Degrees

Masters Medicine University of California, San Diego

Why Is Brian Druker Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Brian J. Druker is a physician-scientist at Oregon Health & Science University , in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, Associate Dean for Oncology in the OHSU School of Medicine, and professor of medicine.

(See a Problem?)

Brian Druker's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (2001) (5035)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (2002) (4091)
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells (1996) (3664)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (2003) (3476)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) (3337)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. (2001) (2772)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (2003) (2202)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (2002) (2065)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. (2001) (2059)
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. (2000) (1363)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia. (2005) (1238)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002) (1196)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. (2006) (1186)
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. (1996) (1124)
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. (2009) (1089)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. (2005) (1069)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. (2002) (1068)
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. (2000) (1059)
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. (2000) (889)
Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017) (754)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. (2011) (745)
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. (2011) (724)
Ponatinib in refractory Philadelphia chromosome-positive leukemias. (2012) (677)
International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (2009) (659)
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. (2002) (652)
Functional Genomic Landscape of Acute Myeloid Leukemia (2018) (639)
Translation of the Philadelphia chromosome into therapy for CML. (2008) (636)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007) (608)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. (2008) (599)
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. (1997) (579)
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. (2002) (574)
Gene expression changes associated with progression and response in chronic myeloid leukemia. (2006) (570)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2010) (516)
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. (2004) (475)
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. (2013) (474)
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. (2006) (467)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). (2010) (463)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2009) (422)
Practical management of patients with chronic myeloid leukemia receiving imatinib. (2003) (403)
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. (2006) (379)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. (2005) (377)
Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics (2003) (363)
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. (2007) (349)
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (2006) (346)
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib (2003) (341)
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. (2005) (337)
Activating alleles of JAK3 in acute megakaryoblastic leukemia. (2006) (333)
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. (2003) (331)
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. (2000) (330)
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. (1994) (296)
Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome (2001) (293)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. (2009) (288)
Perspectives on the development of a molecularly targeted agent. (2002) (282)
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. (2014) (282)
Imatinib as a paradigm of targeted therapies. (2004) (276)
Protein tyrosine kinases and cancer. (1997) (274)
The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. (1998) (271)
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. (2010) (266)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. (2006) (259)
Oncogenes, growth factors, and signal transduction. (1989) (257)
Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. (1990) (253)
STI571 (Gleevec) as a paradigm for cancer therapy. (2002) (250)
The colony stimulating factor-1 receptor associates with and activates phosphatidylinositol-3 kinase (1989) (247)
Chronic myelogenous leukemia (2001) (247)
Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate (1988) (242)
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. (2010) (234)
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. (2006) (233)
STI571: targeting BCR-ABL as therapy for CML. (2001) (232)
Chronic myeloid leukemia: current treatment options. (2001) (228)
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). (2002) (224)
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. (2008) (223)
Presence of an SH2 domain in the actin-binding protein tensin. (1991) (220)
hOCT 1 and resistance to imatinib. (2005) (219)
STI571: a paradigm of new agents for cancer therapeutics. (2002) (217)
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. (2011) (214)
Characterization of murine JAK2V617F-positive myeloproliferative disease. (2006) (212)
Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. (1992) (211)
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. (2003) (210)
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9 (2002) (209)
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. (2013) (207)
Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib (2006) (206)
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. (2007) (203)
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. (1996) (203)
The SH3 Domain-binding T Cell Tyrosyl Phosphoprotein p120 (1995) (197)
Proteogenomic Characterization of Endometrial Carcinoma (2020) (194)
Roots of Clinical Resistance to STI-571 Cancer Therapy (2001) (188)
Cbl-mediated Negative Regulation of the Syk Tyrosine Kinase (1998) (181)
Targeted CML therapy: controlling drug resistance, seeking cure. (2006) (180)
Stimulation through the T Cell Receptor Induces Cbl Association with Crk Proteins and the Guanine Nucleotide Exchange Protein C3G (*) (1996) (177)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. (2019) (177)
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. (2004) (177)
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. (1996) (176)
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells (2010) (175)
Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571* (2002) (175)
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia (2011) (171)
An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase (1991) (168)
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. (2010) (165)
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. (2012) (163)
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. (2002) (160)
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. (2012) (160)
p120 Is a Major Substrate of Tyrosine Phosphorylation upon B Cell Antigen Receptor Stimulation and Interacts in Vivo with Fyn and Syk Tyrosine Kinases, Grb2 and Shc Adaptors, and the p85 Subunit of Phosphatidylinositol 3-Kinase (*) (1996) (157)
Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. (2007) (157)
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. (2019) (156)
Response and Resistance to BCR-ABL1-Targeted Therapies. (2020) (155)
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. (2017) (151)
Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. (1994) (151)
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. (2013) (150)
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. (1994) (150)
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia (2010) (149)
Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM‐CSF, IL‐3 and steel factor and is constitutively increased by p210BCR/ABL. (1995) (149)
Kaposi's Sarcoma-Associated Herpesvirus-Induced Upregulation of the c-kit Proto-Oncogene, as Identified by Gene Expression Profiling, Is Essential for the Transformation of Endothelial Cells (2002) (149)
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. (2006) (146)
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. (2004) (145)
CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells (*) (1995) (142)
Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies (2011) (142)
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response (2007) (141)
The non‐receptor tyrosine kinase Syk is a target of Cbl‐mediated ubiquitylation upon B‐cell receptor stimulation (2001) (136)
Perspective: a program to improve protein biomarker discovery for cancer. (2005) (136)
Circumventing resistance to kinase-inhibitor therapy. (2006) (132)
Activation of a CrkL-Stat5 Signaling Complex by Type I Interferons* (1999) (130)
The Related Adhesion Focal Tyrosine Kinase Differentially Phosphorylates p130Cas and the Cas-like Protein, p105HEF1 * (1997) (129)
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer (2015) (129)
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. (2004) (129)
Differential Expression of Novel Tyrosine Kinase Substrates during Breast Cancer Development *S (2007) (126)
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. (2013) (125)
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells (2007) (124)
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. (2004) (121)
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate (2003) (121)
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML (2002) (121)
Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571) (2004) (120)
Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. (1996) (120)
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. (2011) (118)
Applying the discovery of the Philadelphia chromosome. (2007) (116)
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. (2009) (116)
pp60src is an endogenous substrate for calpain in human blood platelets. (1993) (114)
Chronic myelogenous leukemia. (2009) (114)
A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia (2014) (113)
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. (2002) (113)
Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. (1991) (113)
Imatinib as a paradigm of targeted therapies (2003) (112)
The effect of prior exposure to imatinib on transplant-related mortality. (2006) (112)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : an analysis from the International Randomized Study of Interferon and STI 571 ( IRIS ) * (2010) (111)
Imatinib alone and in combination for chronic myeloid leukemia. (2003) (110)
Ocular side-effects associated with imatinib mesylate (Gleevec). (2003) (110)
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. (2015) (109)
Perspectives on the development of imatinib and the future of cancer research (2009) (109)
Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia (2014) (109)
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. (2004) (108)
RAFTK, a Novel Member of the Focal Adhesion Kinase Family, Is Phosphorylated and Associates with Signaling Molecules upon Activation of Mature T Lymphocytes (1997) (107)
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins (2013) (107)
AMN107: tightening the grip of imatinib. (2005) (107)
Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib (2005) (106)
RNAi screen for rapid therapeutic target identification in leukemia patients (2009) (106)
Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. (2000) (104)
Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. (1997) (104)
The Linker Phosphorylation Site Tyr292 Mediates the Negative Regulatory Effect of Cbl on ZAP-70 in T Cells1 (2000) (104)
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. (2019) (102)
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. (2002) (102)
The Type I Interferon Receptor Mediates Tyrosine Phosphorylation of the CrkL Adaptor Protein* (1997) (102)
Proteogenomic characterization of pancreatic ductal adenocarcinoma (2021) (101)
The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. (2013) (100)
Bcr-Abl inhibition as a modality of CML therapeutics. (2001) (100)
TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor (1999) (99)
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. (2007) (99)
Involvement of p130Cas and p105HEF1, a Novel Cas-like Docking Protein, in a Cytoskeleton-dependent Signaling Pathway Initiated by Ligation of Integrin or Antigen Receptor on Human B Cells* (1997) (98)
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (2009) (97)
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. (1993) (96)
Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. (1992) (95)
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. (2005) (95)
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial (2012) (95)
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. (2011) (95)
Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce rapid phosphorylation and activation of the proto-oncogene Raf-1 in a human factor-dependent myeloid cell line. (1991) (95)
The RING Finger Domain of Cbl Is Essential for Negative Regulation of the Syk Tyrosine Kinase* (2000) (95)
The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior–like Symptoms in a Mouse Model of Cancer Chemotherapy–Related Symptoms (2006) (94)
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation. (2019) (93)
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib (2007) (93)
Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia (2012) (93)
T Cell Activation-dependent Association between the p85 Subunit of the Phosphatidylinositol 3-Kinase and Grb2/Phospholipase C-γ1-binding Phosphotyrosyl Protein pp36/38 (*) (1995) (92)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. (2016) (91)
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. (1994) (91)
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors (2015) (90)
Collagen induces tyrosine phosphorylation of Wiskott-Aldrich syndrome protein in human platelets. (1998) (89)
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. (1997) (89)
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. (2010) (88)
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms (2019) (88)
An expanded universe of cancer targets (2021) (86)
Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. (2006) (85)
Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. (2015) (84)
Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. (2015) (84)
Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic Cells (1998) (84)
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia (2019) (84)
Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. (1997) (83)
Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets (1995) (83)
Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. (2004) (82)
Biochemical identification of a direct physical interaction between the CD4: p56lck and Ti(TcR)/CD3 complexes (1991) (82)
Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study. (2006) (81)
BCR-ABL-induced adhesion defects are tyrosine kinase-independent. (2002) (81)
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. (2011) (81)
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. (2008) (80)
Association of pp60src with Triton X-100-insoluble residue in human blood platelets requires platelet aggregation and actin polymerization. (1992) (79)
Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. (1994) (78)
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. (2010) (77)
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies (2017) (77)
A proteogenomic portrait of lung squamous cell carcinoma (2021) (77)
MET receptor sequence variants R970C and T992I lack transforming capacity. (2010) (75)
Functional implications of tyrosine protein phosphorylation in platelets. Simultaneous studies with different agonists and inhibitors. (1992) (75)
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. (2005) (74)
Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. (1995) (74)
Recent advancements in the treatment of chronic myelogenous leukemia. (2002) (73)
Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product (1991) (73)
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. (2000) (72)
Rapid T-cell receptor-mediated tyrosine phosphorylation of p120, an Fyn/Lck Src homology 3 domain-binding protein. (1994) (72)
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. (2005) (72)
Vav binds to several SH2/SH3 containing proteins in activated lymphocytes. (1994) (72)
Identification of ezrin as an 81-kDa tyrosine-phosphorylated protein in T cells. (1992) (71)
Erythropoietin induces the association of phosphatidylinositol 3'-kinase with a tyrosine-phosphorylated protein complex containing the erythropoietin receptor. (1993) (71)
The T cell receptor/CD3 complex and CD2 stimulate the tyrosine phosphorylation of indistinguishable patterns of polypeptides in the human T leukemic cell line Jurkat (1991) (71)
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. (2004) (71)
Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway* (2008) (70)
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition (2017) (70)
Inhibition of p38 MAPK Suppresses Inflammatory Cytokine Induction by Etoposide, 5-Fluorouracil, and Doxorubicin without Affecting Tumoricidal Activity (2008) (70)
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid Cells* (1997) (70)
IFN-γ Activates the C3G/Rap1 Signaling Pathway1 (2000) (69)
Lessons learned from the development of imatinib. (2004) (69)
Characterization of pp85, a target of oncogenes and growth factor receptors (1990) (68)
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial (2020) (67)
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia (2014) (65)
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. (2008) (65)
Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target (2013) (65)
STI571 as a Targeted Therapy for CML (2003) (65)
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor (2014) (64)
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of rapamycin in leukemic cells (2005) (63)
Human granulocyte-macrophage colony-stimulating factor receptor signal transduction requires the proximal cytoplasmic domains of the alpha and beta subunits. (1993) (63)
TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. (2000) (62)
The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia , but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia (2005) (62)
Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells (2005) (62)
Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. (2006) (62)
The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. (2015) (62)
Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. (1991) (61)
Survey of Activated FLT3 Signaling in Leukemia (2011) (61)
Transformation-defective mutants of polyomavirus middle T antigen associate with phosphatidylinositol 3-kinase (PI 3-kinase) but are unable to maintain wild-type levels of PI 3-kinase products in intact cells (1992) (61)
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia (2016) (61)
Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line. (1991) (60)
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. (2007) (60)
Inhibition of Polysome Assembly Enhances Imatinib Activity against Chronic Myelogenous Leukemia and Overcomes Imatinib Resistance (2008) (59)
IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. (2007) (59)
Molecularly targeted therapy: have the floodgates opened? (2004) (58)
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. (2008) (58)
CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. (1999) (57)
Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia Patients with Defective Growth Hormone Response to Exercise. (2010) (57)
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia (2014) (55)
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. (2005) (55)
Identification of the Src family kinases, Lck and Fgr in platelets. Their tyrosine phosphorylation status and subcellular distribution compared with other Src family members. (1997) (54)
Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. (1992) (53)
High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial (2009) (53)
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. (2014) (53)
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. (2007) (53)
Regulation of Integrin-mediated p130Cas Tyrosine Phosphorylation in Human B Cells (1997) (52)
Interaction of the receptor tyrosine kinase p145c‐kit with the p210bcr/abl kinase in myeloid cells (1996) (52)
CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells. (2000) (52)
Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. (2019) (51)
Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells. (2003) (51)
Tyrosine phosphorylation of α tubulin in human T lymphocytes (1994) (50)
Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. (1996) (50)
Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia (2012) (49)
The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia (2013) (49)
Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerization* (2014) (49)
FTY 720 , a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome – positive acute lymphocytic leukemia (2007) (49)
rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils. (1994) (49)
Phospholipase C-gamma 1 association with CD3 structure in T cells (1992) (48)
Chronic myelogenous leukaemia – new therapeutic principles (2001) (48)
Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. (2019) (48)
Erythropoietin Induces Tyrosine Phosphorylation of Jak2, STAT5A, and STAT5B in Primary Cultured Human Erythroid Precursors (1998) (48)
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. (2019) (48)
Thrombopoietin and thrombin induce tyrosine phosphorylation of Vav in human blood platelets. (1997) (47)
Granulocyte‐Macrophage colony‐stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor‐dependent hematopoietic cell line (1992) (47)
Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells (2007) (47)
Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. (2001) (47)
Imatinib mesylate in the treatment of chronic myeloid leukaemia (2003) (46)
STI571: A gene product-targeted therapy for leukemia (2001) (46)
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma (2015) (45)
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study (2014) (45)
PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl (1996) (44)
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. (2002) (44)
Will imatinib compromise reproductive capacity? (2011) (44)
Genomics: The breast cancer landscape (2012) (44)
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. (2004) (44)
Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. (1997) (43)
Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors. (1998) (43)
Point mutations in the conserved box 1 region inactivate the human granulocyte colony-stimulating factor receptor for growth signal transduction and tyrosine phosphorylation of p75c-rel. (1995) (43)
RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. (2005) (43)
The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. (2001) (43)
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. (2007) (42)
Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers (2004) (42)
STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy (2001) (42)
TMB-8 and dibucaine induce tyrosine phosphorylation and dephosphorylation of a common set of proteins in platelets. (1995) (42)
p120c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin. (1996) (42)
The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. (1995) (41)
PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. (1996) (41)
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia (2020) (41)
The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1. (2002) (41)
FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells (2019) (40)
Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia (2000) (40)
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. (2021) (39)
Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation. (1992) (39)
Overcoming resistance to imatinib by combining targeted agents. (2003) (38)
Dissociation of the Jak kinase pathway from G-CSF receptor signaling in neutrophils. (1997) (38)
Imatinib resistant BCR‐ABL1 mutations at relapse in children with Ph+ALL: a Children's Oncology Group (COG) study (2012) (38)
A completely transformation-defective point mutant of polyomavirus middle T antigen which retains full associated phosphatidylinositol kinase activity (1990) (38)
David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. (2003) (38)
Binding of Cbl to a Phospholipase Cγ1-docking Site on Platelet-derived Growth Factor Receptor β Provides a Dual Mechanism of Negative Regulation* (2007) (38)
24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP). (2009) (37)
CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy (2017) (37)
Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. (1995) (37)
Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma (2018) (37)
The NIH BD2K center for big data in translational genomics (2015) (36)
A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. (2010) (36)
Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics (2007) (36)
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma (2020) (36)
A Functional Genomics Approach to Kaposi's Sarcoma (2002) (36)
Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation. (2004) (36)
Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. (2003) (35)
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. (2011) (35)
Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38) (2010) (35)
Therapeutic drug monitoring in CML patients on imatinib. (2007) (35)
A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. (2012) (35)
Engagement of the CrkL adaptor in interferon α signalling in BCR–ABL‐expressing cells (2001) (35)
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia (2008) (34)
Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia (2015) (34)
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes (2018) (33)
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples (2018) (33)
Tyrosine kinase inhibitors in chronic myeloid leukemia. (1999) (33)
Interactions of p62 dok with p210 bcr-abl and Bcr-Abl-associated Proteins* (1998) (33)
Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. (2016) (33)
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. (2012) (32)
FANCL ubiquitinates β-catenin and enhances its nuclear function. (2011) (32)
Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy (2001) (32)
Time to Complete Cytogenetic Response (CCyR) Does Not Affect Long-Term Outcomes for Patients on Imatinib Therapy. (2007) (31)
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. (1997) (31)
TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. (1999) (31)
Dynamic and Nuclear Expression of PDGFRα and IGF-1R in Alveolar Rhabdomyosarcoma (2013) (31)
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. (2002) (31)
Thrombopoietin induces association of Crkl with STAT5 but not STAT3 in human platelets. (1998) (31)
Chronic myeloid leukemia in the imatinib era. (2003) (30)
Mutant calreticulin‐expressing cells induce monocyte hyperreactivity through a paracrine mechanism (2016) (30)
A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice (2009) (30)
A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial (2010) (30)
Internalization of the granulocyte-macrophage colony-stimulating factor receptor is not required for induction of protein tyrosine phosphorylation in human myeloid cells. (1991) (30)
Identification of the 70kD heat shock cognate protein (Hsc70) and alpha-actinin-1 as novel phosphotyrosine-containing proteins in T lymphocytes. (1996) (30)
Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. (2015) (29)
SRCircumventing imatinib resistance. (2004) (29)
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia (2008) (29)
Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase (1997) (28)
CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line. (1995) (28)
YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway (2015) (28)
Revisiting NTRKs as an emerging oncogene in hematological malignancies (2019) (28)
Polyomavirus middle T-antigen NPTY mutants (1992) (28)
Modulation of a Mr 175,000 c-neu receptor isoform in G8/DHFR cells by serum starvation. (1990) (27)
Current treatment approaches for chronic myelogenous leukemia. (2001) (27)
PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma (2014) (27)
IFN-gamma activates the C3G/Rap1 signaling pathway. (2000) (26)
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. (2006) (26)
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. (2014) (26)
Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? (2002) (25)
Single particle quantum dot imaging achieves ultrasensitive detection capabilities for Western immunoblot analysis. (2009) (25)
Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C' Study. (2006) (25)
Imatinib: Paradigm or Anomaly? (2004) (25)
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. (2013) (25)
Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. (2013) (25)
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. (2004) (24)
Inhibition by sodium nitroprusside or PGE1 of tyrosine phosphorylation induced in platelets by thrombin or ADP. (1992) (24)
Discovery and Characterization of Targetable NTRK Point Mutations in Hematologic Neoplasms. (2020) (24)
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia (2012) (24)
The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML (2019) (24)
Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II Study. (2006) (24)
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. (2014) (23)
Chronic myelogenous leukemia. (2001) (23)
Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib (2006) (23)
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. (2013) (23)
Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation. (2007) (23)
Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia. (2017) (22)
No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). (2003) (22)
Thrombopoietin-Induced Signal Transduction and Potentiation of Platelet Activation (1999) (22)
Suppression of Interferon (IFN)-inducible Genes and IFN-mediated Functional Responses in BCR-ABL-expressing Cells* (2008) (22)
Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate (2006) (22)
Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations (2008) (22)
Functional genomic landscape of acute myeloid leukaemia (2018) (22)
Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression. (1994) (21)
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. (2022) (21)
Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML). (2007) (20)
FANCL UBIQUITINATES BETA-CATENIN AND ENHANCES ITS NUCLEAR FUNCTION (2012) (20)
Absence of constitutive EGF receptor activation in ovarian cancer cell lines. (1996) (20)
Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. (2001) (20)
Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells. (2000) (19)
Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia (2020) (19)
Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia (2016) (19)
BIRB-796 is not an effective ABL(T315I) inhibitor (2005) (19)
Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced‐stage Hodgkin's disease (1989) (19)
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. (2017) (19)
Tyrosine phosphorylation of alpha tubulin in human T lymphocytes. (1994) (18)
Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment (2018) (18)
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms (2016) (18)
c-CBL is not required for leukemia induction by Bcr-Abl in mice (2003) (18)
Imatinib (2019) (17)
Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α. (2005) (17)
Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia (2019) (17)
Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy. (2018) (17)
Therapeutically Targetable ALK Mutations in Leukemia. (2015) (17)
Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin (1996) (17)
Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data. (2006) (16)
Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL. (2020) (16)
Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial (2018) (16)
Crosstalk between ROR 1 and the pre-B-Cell Receptor Promotes Survival of t ( 1 ; 19 ) Acute Lymphoblastic Leukemia (2012) (16)
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. (2021) (16)
A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors, (2011) (16)
Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms (2018) (15)
Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy. (2017) (15)
Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia. (2007) (14)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (Journal of Clinical Investigation (2011) 121, 1, (396-409) DOI: 10.1172/JCI35721) (2011) (14)
An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. (2012) (14)
Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS]) (2008) (14)
Erratum: The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase (Journal of Biological Chemistry (2000) 275 (414-422)) (2000) (14)
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors (2017) (14)
TYK 2 – STAT 1 – BCL 2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia (2013) (14)
Corrigendum: Tyrosine phosphorylation of p95(Vav) in myeloid cells is regulated by GM-CSF, IL-3 and Steel factor and is constitutively increased by p210(BCR/ABL) (The EMBO Journal (1995) 14 (257-265)) (1996) (14)
Extracellular calcium mimics the actions of platelet-derived growth factor on mouse fibroblasts. (1992) (14)
BCL 6-mediated repression of p 53 is critical for leukemia stem cell survival in chronic myeloid leukemia (2011) (14)
patients treated with imatinib mesylate prognostic factors for hematologic relapse of chronic phase CML Clonal evolution and lack of cytogenetic response are adverse (2011) (13)
Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study. (2006) (13)
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells (2008) (13)
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. (2013) (13)
Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia (2018) (13)
Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (2010) (12)
Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia (2019) (12)
Predicting response to BET inhibitors using computational modeling: A BEAT AML project study (2019) (12)
Concurrent STAT3, DNMT3A, and TET2 mutations in T‐LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential (2017) (12)
An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia. (2007) (12)
Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies (2018) (12)
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. (2020) (12)
CRKL binding to BCR-ABL and BCR-ABL transformation. (1999) (12)
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B (2021) (12)
Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3 mutation-positive leukemia (2014) (12)
All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells. (2000) (11)
RNAi screen for therapeutic target in leukemia (2009) (11)
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia (2020) (11)
Tyrosine phosphorylation in signal transduction. (1988) (11)
Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I. (2006) (11)
Understanding cancer from the stem cells up (2017) (11)
Comparison of Imatinib, AMN107 and Dasatinib in an Accelerated Cell-Based Mutagenesis Screen. (2005) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Resistance Profiling of BCR-ABL Compound Mutations Linked to Tyrosine Kinase Inhibitor Therapy Failure in Chronic Myeloid Leukemia (2011) (11)
Replication timing alterations in leukemia affect clinically relevant chromosome domains. (2019) (10)
Imatinib: A Viewpoint by Brian J. Druker. (2001) (10)
BCG-induced macrophages as suppressor cells. (1983) (10)
HitWalker: variant prioritization for personalized functional cancer genomics (2013) (10)
Challenges and approaches to implementing master/basket trials in oncology. (2019) (9)
ST1571: a paradigm for clinical trials of molecularly targeted agents. (2001) (9)
Imatinib Dose Escalation Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). (2007) (9)
Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy. (2005) (9)
FGF 2 from marrow microenvironment promotes resistance to FLT 3 inhibitors in acute myeloid leukemia (2017) (9)
The PI3K/Akt1 pathway enhances steady-state levels of FANCL (2013) (9)
Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl. (2004) (9)
Generation of a large library of point mutations in polyoma middle T antigen. (1991) (9)
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia (2020) (9)
Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies (2011) (8)
The BCR-ABL 35 INS insertion / truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia * (2011) (8)
In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse. (2005) (8)
Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations (2017) (8)
A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia (2017) (8)
Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting (2016) (8)
Growth Arrest of BCR-ABL Positive Cells with a Sequence-Specific Polyamide-Chlorambucil Conjugate (2008) (8)
Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP). (2005) (8)
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance (2021) (8)
Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine (2013) (7)
Mapping of polyomavirus middle T domain that is responsible for AP-1 activation (1998) (7)
Surface immunoglobulin-mediated signal transduction involves rapid phosphorylation and activation of the protooncogene product Raf-1 in human B-cells. (1992) (7)
Chronic myeloid leukemia. Sceptical scientists. (2001) (7)
Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial (2019) (7)
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia (2021) (7)
Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON). (2015) (7)
Outcomes by Cytogenetic and Molecular Response at 12 and 18 Months of Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the IRIS Trial. (2006) (6)
Identification and characterization of the BCG cell wall-stimulated suppressor cells in inbred rats. (1982) (6)
Investigation of the Biological Differences between Bcr-Abl Kinase Mutations Resistant to Imatinib. (2004) (6)
study in chronic-phase chronic myeloid leukemia : a subanalysis of the IRIS Imatinib pharmacokinetics and its correlation with response and safety (2008) (6)
Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors (2010) (6)
Atypical, nonfatal, transfusion-associated, acute graft-versus-host disease in a patient with Hodgkin's disease. (1992) (6)
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells (2020) (6)
Survey of Activated FLT 3 Signaling in Leukemia (2011) (6)
Gene expression profiling of CML CD34+ cells prior to imatinib therapy reveals differences between patients with and without subsequent complete cytogenetic response (2005) (6)
BCR-ABL mRNA Levels At and After the Time of a Complete Cytogenetic Response (CCR) Predict the Duration of CCR In Imatinib-Treated Patients with CML Short title: BCR-ABL mRNA levels predict response duration in CML (2006) (6)
Imatinib (Gleevec) as a paradigm of targeted cancer therapies. (2010) (6)
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. (2022) (6)
Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens (2017) (5)
Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells. (2005) (5)
Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia (2016) (5)
Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor (2008) (5)
Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia (2016) (5)
Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia (2015) (5)
Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women. (2016) (5)
Therapeutic drug monitoring in CML patients on imatinib. Authors' reply (2007) (5)
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells define commitment to apoptosis (2013) (5)
Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia (2016) (5)
Chronic Myeloid Leukemia (2007) (5)
Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML (2022) (5)
Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2 (2018) (5)
Down-regulation of cytokeratin 14 gene expression by the polyoma virus middle T antigen is dependent on c-Src association but independent of full transformation in rat liver nonparenchymal epithelial cells. (1996) (5)
Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd (2019) (4)
Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making. (2006) (4)
Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid Leukemia (2016) (4)
Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies. (2005) (4)
Functional characterization of two rare BCR–FGFR1+ leukemias (2020) (4)
Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor (1999) (4)
Synergistic Interactions between Imatinib and the Novel Phosphoinositide-Dependent Kinase-1 Inhibitor OSU-03012 in Overcoming Imatinib Resistance Running title : Overcome imatinib resistance by a PDK-1 inhibitor (2005) (4)
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia (2021) (4)
Effects of Plerixafor (AMD3100) In Combination with Tyrosine Kinase Inhibition In a Murine Model of CML. (2010) (4)
A Gene Expression Signature of CD34+Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance (2009) (4)
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia (2021) (4)
Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) (2014) (4)
Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level (2015) (4)
Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients (2020) (4)
Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia (2018) (4)
Comparison of steady-state imatinib (IM) trough levels, clinical response, and safety between Caucasian and Asian patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with 400mg and 800mg daily doses of IM in the tyrosine kinase inhibi (2009) (4)
RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets (2008) (4)
Understanding Drug Sensitivity and Tackling Resistance in Cancer (2022) (4)
Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy. (2009) (4)
JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model. (2016) (4)
Can we cure CML (2004) (3)
MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β Chain Cytokine Receptor Endocytosis. (2021) (3)
Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL (2015) (3)
Effects of CYT387, a potent novel JAK2 inhibitor on JAK2-V617F induced MPD (2008) (3)
A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A Beat AML Project Study (2016) (3)
Novel Method to Perform Functional Drug Screens on Frozen Primary Leukemia Samples (2015) (3)
The negative systemic effect of BCGcw inoculated intraperitoneally (1981) (3)
The negative systemic effect of BCGcw inoculated intraperitoneally (1981) (3)
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. (2022) (3)
RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies. (2009) (3)
KIT as a Therapeutic Target (2003) (3)
Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms (2021) (3)
Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial (2016) (3)
The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells. (2004) (3)
A precision medicine classification for treatment of acute myeloid leukemia in older patients (2021) (3)
Characterization of Transforming NTRK2 and NTRK3 Mutations Identified in Leukemia Patient Samples (2016) (3)
Kinase Inhibitor Therapy in CML: It's What's Inside That Counts (2013) (3)
The Bromodomain Inhibitor CPI203 Demonstrates Preclinical Synergistic Activity with Bortezomib in Drug Resistant Myeloma (2014) (3)
Kinase Mutat ions and Imat inib Response in Pat ients With Metastat ic Gastro intes t inal Stromal Tumor (2003) (3)
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial (2019) (3)
Imatinib Plasma Concentration and Sokal Risk Score Are Independently Prognostic for Complete Cytogenetic Response (CCyR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP). (2007) (3)
Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations (2021) (3)
Erratum: Association of pp60src with Triton X-100-insoluble residue in human blood platelets requires platelet aggregation and actin polymerization (Journal of Biological Chemistry (1992) 267 (20075-20081)) (1993) (3)
Combining the Allosteric ABL1 Tyrosine Kinase Inhibitor ABL001 with ATP-Competitive Inhibitors to Suppress Resistance in Chronic Myeloid Leukemia (2016) (3)
The AML Microenvironment Catalyzes a Step-Wise Evolution to Gilteritinib Resistance (2021) (3)
Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (2016) (3)
Preclinical Development Potent Activity of Ponatinib ( AP 24534 ) in Models of FLT 3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies (2011) (3)
Detection of Imatinib-Resistant BCR-ABL Mutants in Drug-Naïve Patients: Correlation with Disease Phase and Clonal Evolution but Not with Response to Treatment. (2004) (3)
Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes (2017) (3)
TEL/PDGFβR fusion protein activates STAT1 and STAT5 (2000) (3)
Sceptical scientists (2001) (2)
Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC‐amplified model cell line (2017) (2)
CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes (2015) (2)
JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice. (2005) (2)
Selective Killing of BCR-ABL Positive Cells with a Specific Inhibitor of the ABL Tyrosine Kinase (1996) (2)
In Chronic Lymphocytic Leukemia, Zap70 Identifies a Survival Pathway Signal Cascade Involving p85 PI-3-Kinase, CrkL, and Cbl with Syk En Route to JNK1 and bcl-2. (2006) (2)
Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry. (2010) (2)
Exaggerated Response To Toll-Like Receptor Agonist Contributes To Excessive TNF Production In Myeloproliferative Neoplasm (2013) (2)
A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973 (2012) (2)
JAK2-Mediated Extrinsic Survival of CML Stem Cells: Exploring the Potential Combination of BCR-ABL and JAK2 Inhibitors In Vivo (2010) (2)
Safety and Durability of Ponatinib in Patients With Philadelphia Chromosome–Positive (Ph+) Leukemia: Long-term Follow-up of an Ongoing Phase 1 Study (2014) (2)
OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias (2013) (2)
Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells Are Also Resistant to ABL Inhibitors, Which Can be Overcome By Targeting the PI3K/AKT/ mTOR Pathway (2016) (2)
Six Year Follow-Up Results of a Phase II Study of Imatinib in Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Post Interferon-A (IFN) Refractoriness/Intolerance. (2006) (2)
Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib. (2004) (2)
In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT. (2004) (2)
BCR/ABL modulates the cytokine and retinoic acid response of c-Rel in human myeloid cells. (1996) (2)
Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML (2018) (2)
Cryptic Intracellular Retention of ABL Tyrosine Kinase Inhibitors within CML Cells Mediates Apoptosis Commitment Following Acute Drug Exposure (2011) (2)
Aurora A kinase as a target for therapy in TCF3-HLF rearranged acute lymphoblastic leukemia (2021) (2)
T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia (2018) (2)
Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells (2019) (2)
MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia (2015) (2)
Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial (2020) (2)
Bruton’s Tyrosine Kinase (BTK) Is Not Required for BCR-ABL-Mediated Transformation of Hematopoietic Cells. (2007) (2)
Philadelphia chromosome-positive acute lymphoid leukemias A phase 2 study of imatinib in patients with relapsed or refractory (2009) (2)
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia (2022) (2)
Janet Rowley (1925–2013) (2014) (2)
Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study (2012) (2)
Mutationally Activated TYK2 From T-ALL Specimens Exhibits Tranformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice (2011) (2)
A Transcriptomal Profile for Predicting Complete Cytogenetic Response (CCR) in Chronic Phase CML Patients Treated with Imatinib. (2007) (2)
like Symptoms in a Mouse Model of Cancer Chemotherapy - and Sickness Behavior The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production (2011) (2)
Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture (2019) (1)
Progressive loss of EGFR in a subpopulation of breast cancers: Implications in target-directed therapeutics (2007) (1)
Small-Molecule Inhibitors of Protein Kinases in the Treatment of Human Cancer (2003) (1)
BCR-ABL Lacking the Pleckstrin Homology (PH) Domain of BCR Induces a More Aggressive Leukemia Than P210 BCR-ABL in a Murine Model of CML. (2004) (1)
Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia (2021) (1)
Abstract 5248: Targeted suppression of interleukin-1 signaling inhibits growth of primary human acute myeloid leukemia cells (2014) (1)
Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group. (2009) (1)
CRKL Links p210 with Paxillin in Chronic Myelogenous Leukemia Cells* (1995) (1)
Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen. (2018) (1)
Abstract 1631: FGF2 activation of FGFR1 in head and neck squamous cell carcinoma is associated with more invasive disease and can be attenuated by FGFR inhibition (2016) (1)
P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations (2010) (1)
Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia (2011) (1)
A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control (2018) (1)
Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB2 receptor ( trosine kinases / oncogencs / phophorylation / breast neopsims ) (1)
The Oncogenic Role of Tumor Suppressor Protein p27 in Ph+ Chronic Myeloid Leukemia. (2009) (1)
Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis (2008) (1)
Abstract 2809: Pathway dependence on the tyrosine kinase TYK2 in T-cell acute lymphoblastic leukemia (2011) (1)
Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine (2013) (1)
Single Cell RNA Sequencing Identifies a Crucial Role for ASXL1 in Neutrophil Development (2019) (1)
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial (2019) (1)
An Epstein-Barr VirusProtein Associated withCellGrowth Transformation Interacts witha Tyrosine Kinase (1991) (1)
Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report (2021) (1)
Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia (2018) (1)
Inhibitors of Protein Kinases and Protein Phosphates Contributors (2005) (1)
PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia (2014) (1)
Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study (2017) (1)
Activating Mutations of Insulin Receptor Substrate 2 (IRS2) in Patients with Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia (2015) (1)
Abstract 791: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples (2018) (1)
Suppression of IFN-inducible genes and IFN-mediated functional responses in BCR-ABL expressing cells suppresses expression of IFN-dependent antiviral (2008) (1)
Evaluation of Differential Peptide Loading on Tandem Mass Tag-Based Proteomic and Phosphoproteomic Data Quality (2020) (1)
Variable Retention of Differentiation-specific DNA Replication Timing in Human Pediatric Leukemia (2019) (1)
Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells (2018) (1)
Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph+) leukemia: Long-term follow-up of an ongoing phase I study. (2013) (1)
Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia (2018) (1)
A Novel, High-Throughput Assay for Detection of ABL T315I Mutations. (2006) (1)
Murine Model of Aggressive Systemic Mastocytosis: A Disease Caused by Oncogenic Kit. (2004) (1)
Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia (2022) (1)
Sti 571 induces caspase 9 and 3 dependent apoptosis of bcr-abl positive cells in-vitro; augmentation of apoptotic responses by trail (2000) (1)
Mutations Modifying Risk in NPM1+ AML (2015) (1)
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase‐independent resistance in chronic myeloid leukaemia (2022) (1)
5.50 CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Exhibits CLL Antitumor Activity (2011) (1)
Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study (2022) (1)
Abstract 984: FGF2 from the bone marrow promotes resistance to FLT3 inhibitors in AML (2015) (1)
T Cell Mediated Suppression of Hematopoiesis in Myeloproliferative Neoplasm (2014) (1)
PDGF Receptors as Therapeutic Targets (2003) (1)
A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias (2010) (1)
Developing an Effective Oncology Team. (2007) (1)
Phospholipase C-T 1 Association with CD 3 Structure in T Cells (2003) (1)
Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants (2019) (1)
Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission. (2007) (1)
Feasibility and Toxicity of Nonmyeloablative Hematopoietic Cell Transplantation (HCT) with or without Imatinib for Philadelphia Chromosome (Ph+) Acute Lymphoblastic Leukemia (ALL). (2004) (1)
p27 Is Mislocalized to the Cytoplasm by BCR-ABL In a Kinase-Independent Manner and Contributes to Leukemogenesis (2010) (1)
Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts (2021) (1)
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism (2022) (1)
Novel tyrosine phosphorylation targets of EGF signaling and gefitinib in human cancer cells. (2007) (1)
Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia (2022) (1)
A Novel, Oncogenic CSF2RB Mutation Found in a Primary Leukemia Sample Results in Constitutive Signaling, Increased Receptor Stability, and Formation of Intermolecular Complexes (2015) (1)
resistance remain sensitive to imatinib Several Bcr-Abl kinase domain mutants associated with imatinib mesylate (2013) (1)
Activation switch pocket inhibitors target the T315I mutant of BCR-ABL (2008) (1)
Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study (2018) (1)
Targeting Oncogenes in Hematopoietic Malignancies (2003) (1)
receptor expression in canine cyclic hematopoiesis is not caused by altered G-CSF Abnormal response to granulocyte colony-stimulating factor (G-CSF) (2011) (1)
Consultations in Molecular Diagnostics An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy (2008) (1)
Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia: Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse. (2020) (1)
TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder. (2007) (1)
leukemia not contribute to tyrosine kinase inhibitor resistance in chronic myeloid insertion/truncation mutant is kinase-inactive and does 35INS The BCR-ABL (2012) (1)
Dasatinib Shows Therapeutic Potential in the Murine Xenograft Model for TCF3 rearranged Acute Lymphoblastic Leukemia (2014) (1)
Targeting BCL-2 and BCR-Abl Activity in Ph+ALL (2015) (1)
Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT (2008) (1)
Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia (2022) (1)
Abstract 1323: CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients (2019) (1)
Identification of Effective Targeted Drug Combinations Using Functional Ex Vivo Screening of Primary Patient Specimens (2015) (1)
Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia (2019) (1)
Inhibition of Autophagy in Combination with Ponatinib or Dual PI3K/mTOR Inhibition to Improve Treatment Response for Both Bcr-Abl Dependent and Independent Mechanisms of TKI-Resistance in CML (2012) (1)
Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey (2018) (1)
Clinical Aspects of Imatinib Therapy (2005) (1)
Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies (2016) (1)
Hodgkin ' s Lymphoma Cell Line Tyrosine Kinase and of Mitogen-activated Protein Kinase in a CD 30 Ligand Signal Transduction Involves Activation of a Updated (2006) (0)
Phosphotyrosine proﬁling identiﬁes the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia (2006) (0)
CML with E8A2 BCR-ABL Fusion: The Fourth Breakpoint Cluster Region?. (2004) (0)
STI571: A P aradigm o f N ew A gents f or C ancer T herapeutics (2002) (0)
Abstract 3042: Splicing repressorHNRNPCis an indispensable and 'druggable' target in acute myeloid leukemia (2019) (0)
Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort (2019) (0)
Functional RNAi Screen Identifies Novel Cytokine and Growth Factor Receptors Critical for Leukemia Cell Growth (2012) (0)
High-Throughput Validation of Mutations Identified in Primary Leukemia Cells (2016) (0)
Signal Transduction Inhibitors (2003) (0)
murine model of CML Effects of plerixafor in combination with BCR-ABL kinase inhibition in a (2012) (0)
Elvn-001, a Next Generation ATP-Competitive ABL1 Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia (2022) (0)
A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up (2022) (0)
Metformin Reduces Tumor Burden and Splenomegaly in JAK2V617F Murine Models (2017) (0)
An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy. (2007) (0)
Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO) (2020) (0)
Practical M anagement o f P atients W ith C hronic M yeloid Leukemia R eceiving I matinib (2003) (0)
BCR-ABL+ Chronic Myeloid Leukemia Arising in a Family With Inherited ANKRD26-Related Thrombocytopenia. (2021) (0)
Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report (2021) (0)
mutations and for expressing results transcripts and kinase domain BCR-ABL methodology for detecting inhibitors - Review and recommendations for 'harmonizing' current Monitoring CML patients responding to treatment with tyrosine kinase (2011) (0)
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. (2023) (0)
RNAi Screen Reveals TYK2 as a Novel Therapeutic Gene Target In T-Cell Acute Lymphoblastic Leukemia (2010) (0)
Replication Timing and Pediatric Leukemia (2012) (0)
Abstract 4772: Novel transforming ErbB2 mutations in leukemia (2014) (0)
Therapeutics , Targets , and Chemical Biology KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors (2013) (0)
Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors (2022) (0)
pharmacodynamics myelodysplastic syndrome: safety, pharmacokinetics, and antagonist, in patients with acute myelogenous leukemia or high-risk Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 (2013) (0)
Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia (2019) (0)
Tyrosine phosphorylation ofp95vav inmyeloidcells isregulated byGM-CSF,IL-3andSteelfactorand is constitutively increased byp2IOBCR/ABL (1995) (0)
Kinase M utations a nd I matinib R esponse i n P atients W ith Metastatic G astrointestinal S tromal T umor (2003) (0)
Cancer center support for understanding statewide COVID-19 prevalence and early detection (2020) (0)
CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples (2017) (0)
Development and Repurposing of Small-Molecule Kinase Inhibitors to Target Novel Leukemogenic TNK2 Mutations (2014) (0)
chronic myelogenous leukemia patients: 14 months' experience treated - Hematopathologic and cytogenetic findings in imatinib mesylate (2013) (0)
Peter C. Nowell (1928–2016) (2017) (0)
Reply to D.M. Ross et al and V. Florou et al. (2018) (0)
The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model. (2006) (0)
Jak2 V617F Induced TNF Resistance as a Mechanism of Clonal Expansion In Myeloproliferative Neoplasm (2010) (0)
Cbl on ZAP-70 in T Cells Mediates the Negative Regulatory Effect of 292 The Linker Phosphorylation Site Tyr (2017) (0)
nsformation of Mouse Hematopoietic Progenitors (2010) (0)
Signal transduction, effectors and targets in tumor cells: The interface between basic research and therapeutic intervention (2005) (0)
Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia (2019) (0)
Abstract LT022: The AML microenvironment catalyzes a step-wise evolution to gilteritinib resistance (2021) (0)
Pract ica l Management of Pat ients With Chronic Myelo id Leukemia Receiv ing Imat inib (2003) (0)
STI571: A sea change in cancer therapeutics or a one time event? (2001) (0)
YM155 sensitivity in pediatric acute lymphoblastic leukemia. (2012) (0)
BCR-ABL Transcript Levels at Time of Complete Cytogenetic Remission Achieved after Salvage with Dasatinib or Nilotinib. (2007) (0)
Bcr-abl kinase inhibition as the basis of therapy for cml (2000) (0)
An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients. (2007) (0)
Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL (2012) (0)
Abstract 1980: S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia (2018) (0)
Critical Role Of Interleukin Receptor Signaling In Acute Myeloid Leukemia Identified Using An RNAi Functional Screen (2013) (0)
Oncoproteomic profiling of AML: moving beyond genomics (2022) (0)
Mathematical and Experimental Evidence That Differentiation of Leukemic Blasts in Acute Myeloid Leukemia Is Not Completely Blocked (2019) (0)
CSF3R T618I Mouse Bone Marrow Transplant Model Of Neutrophilic Leukemia (2013) (0)
Abstract 1133: Combined inhibition of cKIT and Lysine-Specific Demethylase 1 as a therapeutic strategy in acute myeloid leukemia (2021) (0)
increases sensitivity to MLN518 RNAi induced downregulation of FLT3 expression in AML cell lines (2013) (0)
Abstract 2760: CSF3R ligand-independent mutations found in chronic neutrophilic leukemia have altered O-linked glycosylation (2014) (0)
Survey of Activated FLT3 Signaling in Leukemia Please share how this access benefits you. Your story matters (2011) (0)
A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib. (2012) (0)
A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing (2017) (0)
TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia (2012) (0)
Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial (2021) (0)
Comprehensive molecular characterization of a rare case of Philadelphia chromosome–positive acute myeloid leukemia (2022) (0)
FLT3 and LSD1 Inhibitor Combinations Synergistically Repress Growth of FLT3-Mutant Acute Myeloid Leukemia Via Blockage of MYC Function (2020) (0)
Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study (2018) (0)
Comprehensive characterization of VISTA expression in patients with acute myeloid leukemia. (2016) (0)
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. (2023) (0)
A new class of thienopyrimidine Src inhibitors demonstrates potent growth suppression of imatinib resistant Ba/F3 cells harboring a wide range of BCR-ABL mutations, including the CML relevant T315I (2007) (0)
Targeted Suppression of Interleukin-1 Signaling Attenuates Leukemic Cellular Growth and Disease Progression in Primary Human Cells and Murine Models of Acute Myeloid leukemia (2014) (0)
Associating Ex Vivo Drug Sensitivity with Differentiation Status Identifies Effective Drug Combinations for Acute Myeloid Leukemia (2021) (0)
Identification of Targeted Therapies for Rare Adult Mature T-Cell Leukemia Using Functional Ex Vivo Screening of Primary Patient Samples (2016) (0)
Abstract 3883: Gene expression predictsex vivodrug sensitivity in acute myeloid leukemia (2018) (0)
Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias (2018) (0)
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. (2022) (0)
Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness (2018) (0)
Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation. (2008) (0)
Dual PI3K/mTOR inhibition in combination with inhibition of autophagy to improve treatment response for BCR-ABL independent mechanisms of TKI-resistance in CML (2015) (0)
Considerations in Clinical Trial Design for Tyrosine Kinase Inhibitors (2003) (0)
Immune checkpoint inhibitors reverse T-cell functional suppression in the bone marrow of a subset of AML patients (2019) (0)
Toxicity of TKIs (2003) (0)
Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia. (2006) (0)
Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML (2022) (0)
Rac GTPases Are Potential Therapeutic Targets in p210-BCR-ABL-Induced Myeloproliferative Disease (MPD). (2007) (0)
ARG (Abelson-Related Gene) as a Therapeutic Target (2003) (0)
Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial (2021) (0)
Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia (2011) (0)
positive cells - other antileukemic agents against Bcr-Abl Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with (2013) (0)
does not require interaction of p85 SH2 domains with p210 BCR/abl PI 3-kinase activation in BCR/abl-transformed hematopoietic cells (2011) (0)
Suppression of immunological responsiveness by immunization with Bacillus Calmette-Guerin cell walls (BCGcw): In vivo studies (1981) (0)
A Blunted Response to the Anti-Inflammatory Cytokine IL-10 Contributes to Excessive TNF Production in Myeloproliferative Neoplasm (2015) (0)
The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia (2015) (0)
DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia (2019) (0)
To the editor : Measles in bone marrow transplant recipients (2002) (0)
Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia (2023) (0)
Chronic-Phase Chronic Myeloid Leukemia Times to Death By Disease Support Tyrosine Kinase Inhibitor Dose Reductions When BCR::ABL1 Level Is <1% and Decreasing (2022) (0)
Dual Targeting of FLT3 and LSD1 Disrupts the MYC Super-Enhancer Complex in Acute Myeloid Leukemia (2022) (0)
Therapeutically Targetable ALK Mutations in (2015) (0)
Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia (2018) (0)
RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients. (2007) (0)
Treatment options in chronic myelogenous leukemia. Authors' reply (2002) (0)
Cancer esearch or and Stem Cell Biology pecific Need for CRKL in p 210 BCR-ABL – Induced R nsformation of Mouse Hematopoietic Progenitors (2010) (0)
Novel Targets Identified By in Vitro Screening of Patient Samples with Adult Acute Lymphoblastic Leukemia (2016) (0)
Abstract B36: Induction of IL-6 by breast cancer chemotherapy mediates loss of fat-free lean body mass in tumor-free mice by decreasing systemic IGF-1 (2010) (0)
A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells (2010) (0)
a Tyrosine Kinase Inhibitor , Inhibits the Growth of Cells (1997) (0)
Abstract 4158: Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through a novel BCR-ABL inhibitor (2017) (0)
Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial (2021) (0)
Abstract 3269: Dual targeting of FLT3 and LSD1 disrupts the MYC super-enhancer complex in acute myeloid leukemia (2022) (0)
Abstract 2282: Rapid identification of targetable CSF3R mutations that define neutrophilic leukemia by combining functional and genomic screens. (2013) (0)
BCR-ABL RNA Levels at the Time of a Complete Cytogenetic Response (CCR) Predict the Duration of CCR in Imatinib-Treated Chronic Myeloid Leukemia Patients. (2004) (0)
A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML) (2022) (0)
Abstract 4538: Global and phosphoproteomic analysis of AML cell line response to phosphatase inhibitor treatment (2019) (0)
The blocking of tumor and allograft immune responses by bacillus calmette guerin cell walls (BCGcw): A suppressor cell phenomenon (1981) (0)
Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial (2021) (0)
acute lymphoblastic The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic (2005) (0)
1 TYK 2-STAT 1-BCL 2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia (2013) (0)
Mutants de domaines de la kinase de l'ABL (2002) (0)
study of FGFR1 fusions in acute myeloid leukemia Phosphotyrosine profiling identifies the KG-1 cell line as a model for the (2013) (0)
Mutant of the kinase domain of ABL (2002) (0)
A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies (2016) (0)
Abstract PO-057: Cancer center support for understanding statewide COVID-19 prevalence and early detection (2020) (0)
Regulation of FANCL by Glycogen Synthase Kinase-3beta Links the Fanconi anemia pathway to Self Renewal and Survival Signals (2012) (0)
Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F. (2009) (0)
Recurrent mutations in the epigenetic regulator Additional Sex-Combs Like 1 ( ASXL 1 ) are associated with universally poor prognosis in myeloid malignancy (2022) (0)
Abstract 38: Secondary fusions as a mechanism of BCR-ABL1 kinase-independent resistance in chronic myeloid leukemia (2021) (0)
Abstract 926: Extrinsic and intrinsic activation of RAS/MAPK signaling enables resistance to FLT3 inhibitor, gilteritinib, in acute myeloid leukemia (2019) (0)
AP23848 against activation loop mutants of Kit In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and (2013) (0)
2.31 Phosphoinositide 3'-Kinase (PI3K) Delta Inhibition with CAL-101 (GS 1101) Significantly Alters Chemokines and Shows Increased In Vitro Activity in Unmutated IgVh CLL Compared to Mutated IgVh Samples (2011) (0)
Phosphoproteome of activated FLT3 in leukemia (2007) (0)
Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors (2013) (0)
FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance (2013) (0)
Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations (2017) (0)
Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation. (2010) (0)
Suppression of CML Progenitor but Not Stem Cells Requires Simultaneous Inhibition of KIT and BCR-ABL1. (2012) (0)
Analysis of protein-protein interactions in cell lines expressing bcr-ablmutants (2000) (0)
Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia (2018) (0)
Combining Dose-Response Slope with in Vitro Sensitivity to ABL Tyrosine Kinase Inhibitors As an Improved Correlative Metric for Predicting Clinical Response in Chronic Myeloid Leukemia (2012) (0)
A gene polymorphism within the kinase domain of BCR-ABL and its effects on sensitivity to tyrosine kinase inhibitors (2005) (0)
Bull's-Eyes and Blind Spots: Pre-Clinical Studies with the Allosteric Inhibitor ABL001 in BCR-ABL1 Compound Mutation-Based Resistance (2015) (0)
Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax) (2015) (0)
Abstract 2705: Functional proteomics to reveal distinct signature for acute myeloid leukemia subtypes (2018) (0)
Multi-color Flow Cytometry-based Interrogation of Survival and Apoptotic Signaling After Exposure of Leukemia Cells to Tyrosine Kinase Inhibitors (2010) (0)
Tyrosine Kinase Inhibitors: Targeting Considerations (2003) (0)
Short title: FLT3 antagonist tandutinib in AML or high-risk MDS (2006) (0)
RNAi Identifies Survivin as a Potential Target for Therapy In Pediatric Acute Lymphoblastic Leukemia (2010) (0)
Abstract 3172: Mapping the molecular landscape of acute myeloid leukemia enables prediction of drug response from proteogenomic data (2023) (0)
CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies, (2011) (0)
The Tumor Suppressors, MS4A3 and G0S2, Are Downregulated in CML Cells with BCR-ABL1 Kinase-Independent Resistance (2014) (0)
Human Platelets Thrombopoietin Induces Association of Crkl With STAT5 But Not STAT3 in (2013) (0)
Evolution of Gilteritinib Resistance from Residual Disease to Relapse (2020) (0)
chronic-phase chronic myeloid leukemia after failure of imatinib therapy Dasatinib induces notable hematologic and cytogenetic responses in (2013) (0)
Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors. (2005) (0)
Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study (2017) (0)
Reply to N. Cerveira et al. (2019) (0)
Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells (2000) (0)
ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic Leukemia (2010) (0)
Abstract 5125: Evaluation of differential peptide loading on TMT-based proteomic on phosphoproteomic data quality in an AML model (2020) (0)
study : Presented in part at the 43rd Annual Meeting of The American chronic myelogenous leukemia in myeloid blast crisis: results of a phase II Imatinib induces hematologic and cytogenetic responses in patients with (2013) (0)
expressing results transcripts and kinase domainBCR-ABLmethodology for detecting inhibitors : review and recommendations for harmonizing current Monitoring CML patients responding to treatment with tyrosine kinase (2006) (0)
A Bcr-Abl Mutant Lacking Direct Binding Sites for the Grb2, Cbl and CrkL Adapter Proteins Fails to Induce Leukemia in Mice. (2004) (0)
Imatinib: profile report (2002) (0)
DEFINING THE IMMUNE MICROENVIRONMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (2015) (0)
Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies. (2005) (0)
phosphorylation in human myeloid cells factor receptor is not required for induction of protein tyrosine Internalization of the granulocyte-macrophage colony-stimulating (2011) (0)
Abstract B019: ASO-mediated NRAS knockdown overcomes gilteritinib late resistance in FLT3-AML (2023) (0)
Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms (2018) (0)
Mechanisms of Disease Persistence in Chronic Myelogenous Leukemia (CML) (2006) (0)
Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival (2014) (0)
Pharmacological IRS1/2 inhibition induces apoptosis in BCR-ABL1T315I mutant cells (2016) (0)
Abstract 325: A genome-wide CRISPR screen on AML cells reveals the TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition (2019) (0)
High dimensional mapping of temporal evolution within the marrow microenvironment in response to FLT3 inhibitor therapy. (2021) (0)
Long-term Results of Ponatinib in CP-CML: 4-Year Minimum Follow-up of a Phase 1 Trial (2015) (0)
neoplasms normalizes inflammatory cytokines in murine myeloproliferative CYT387, a novel JAK2 inhibitor, induces hematologic responses and (2011) (0)
Imatinib as a paradigm of targeted cancer therapies (2007) (0)
ASXL1 Directs Neutrophilic Differentiation via Modulation of MYC and RNA Polymerase II (2020) (0)
with imatinib response in chronic-phase chronic myeloid leukemia patients treated cells to predict major cytogenetic + A gene expression signature of CD34 (2011) (0)
PNAS Plus Significance Statements (2015) (0)
study of FGFR1 fusions in acute myeloid leukemia Running Title: FGFR1OP2-FGFR1 fusion in the KG-1 cell line (2016) (0)
Abstract A15: Computational modeling of methylation impact of AML driver events (2023) (0)
clinical response to ABL kinase inhibitors in chronic myeloid leukemia Integrating in vitro sensitivity and dose-response slope is predictive of (2014) (0)
Recurrent Pathogenic Cyclin D2 Mutations in Myeloid Malignancies (2016) (0)
Abstract 2333: Functional RNAi screen identifies novel cytokine and growth factor receptors critical for the growth of leukemia patient samples. (2013) (0)
leukemia or chronic lymphocytic leukemia leukemia and acute myeloid leukemia, but not in acute lymphoblastic The JAK2V617F activating mutation occurs in chronic myelomonocytic (2013) (0)
CML-109: Exploratory Biomarker Analysis from ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) from Poor Response in Chronic Myeloid Leukemia (CML) (2020) (0)
Abstract 4971: FGF2 promotes resistance to ABL kinase inhibitors in CML. (2013) (0)
FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations (2016) (0)
The dual SRC-ABL inhibitors in Ph+ acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors. (2015) (0)
Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging (2018) (0)
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms (2019) (0)
Running Title: Nuclear Receptor Tyrosine Kinases in Rhabdomyosarcoma (2013) (0)
Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia (2017) (0)
Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib. (2005) (0)
Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia (2020) (0)
FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib (2013) (0)
Abstract 970: Transforming NTRK2 and NTRK3 mutations as potential drivers of leukemia (2018) (0)
Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy (2022) (0)
acute myeloid leukemia RNAi screening of the tyrosine kinome identifies therapeutic targets in (2013) (0)
Imatinib (Glivec®) as a paradigm of targeted cancer therapies (2014) (0)
CX-4945, an Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Exhibits Synergy When Combined with the PI3K-Δ Inhibitor GS-1101 or Fludarabine. (2012) (0)
Activating Mutations Observed in De Novo Acute Myeloid Leukemia Are Also Present in a Subset of Philadelphia Chromosome (Ph)-Positive Leukemia Patients with BCR-ABL1-Independent Resistance to ABL1 Kinase Inhibitors (2014) (0)
patients on imatinib BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia (2011) (0)
Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis. (2009) (0)
FGF2-Containing Exosomes Secreted from Bone Marrow Stromal Cells Protect Leukemia Cells from Tyrosine Kinase Inhibitors (2015) (0)
Strategies to Inhibit Tyrosine Kinases (2003) (0)
Targeting Isoprenylcysteine Carboxyl Methyltransferase to Overcome Resistance and Improve Responses in Chronic Myeloid Leukemia. (2009) (0)
Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study (2017) (0)
A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis. (2006) (0)
MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia (2016) (0)
A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression. (2006) (0)
TITLE: FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia Short title: FGF2 PROMOTES RESISTANCE IN FLT3 AML (2016) (0)
The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization (2013) (0)
Abstract B35: Serum inflammatory biomarkers of acute and persistent fatigue in a preclinical breast cancer treatment model (2010) (0)
malignant hematopoiesis Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and (2013) (0)
Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia (2010) (0)
Clonal Hematopoiesis in Older Women with Extremely Skewed, Non-Random X-Inactivation Is Associated with Previous Cardiovascular and Cerebrovascular Events (2018) (0)
The PI3K/Akt1 pathway enhances steady state levels of FANCL (2013) (0)
mutations in myeloid leukemia patients High-throughput sequencing screen reveals novel, transforming RAS (2013) (0)
Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML (2019) (0)

This paper list is powered by the following services:

Other Resources About Brian Druker

en.wikipedia.org

What Schools Are Affiliated With Brian Druker?

Brian Druker is affiliated with the following schools:

Image Attributions

Image Source for Brian Druker